Natixis’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.62M | Buy |
151,300
+151,250
| +302,500% | +$3.61M | 0.02% | 377 |
|
|
2025
Q1 | $1.24K | Sell |
50
-92,200
| -100% | -$2.29M | ﹤0.01% | 903 |
|
|
2024
Q4 | $1.74M | Buy |
+92,250
| New | +$1.74M | 0.01% | 480 |
|
|
2024
Q3 | – | Sell |
-118,250
| Closed | -$3.38M | – | 1062 |
|
|
2024
Q2 | $3.38M | Buy |
118,250
+115,000
| +3,538% | +$3.29M | 0.02% | 329 |
|
|
2024
Q1 | $95K | Buy |
+3,250
| New | +$95K | ﹤0.01% | 763 |
|
|
2023
Q4 | – | Sell |
-21,500
| Closed | -$660K | – | 1119 |
|
|
2023
Q3 | $660K | Buy |
21,500
+6,000
| +39% | +$184K | 0.01% | 552 |
|
|
2023
Q2 | $621K | Sell |
15,500
-13,000
| -46% | -$521K | 0.01% | 600 |
|
|
2023
Q1 | $1.16M | Buy |
+28,500
| New | +$1.16M | 0.01% | 490 |
|
|
2022
Q4 | – | Sell |
-25,250
| Closed | -$1.34M | – | 1180 |
|
|
2022
Q3 | $1.34M | Buy |
+25,250
| New | +$1.34M | 0.01% | 663 |
|